←Back to Expert Scholars
Translational Medicine / 转化医学Breast Cancer, Post-Progression CDK4/6
Sara Hurvitz
MD
🏢Fred Hutchinson Cancer Center🌐USA
Senior Vice President, Clinical Research Division
68
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Sara Hurvitz has led multiple trials examining therapy after CDK4/6 inhibitor progression including postMONARCH and next-line combinations. She has also directed key DESTINY trials of trastuzumab deruxtecan. She now leads clinical research at Fred Hutch.
Share:
🧪Research Fields 研究领域
postMONARCH
post-CDK4/6 strategies
HER2 breast trials
T-DXd DESTINY trials
tucatinib
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Sara Hurvitz 的研究动态
Follow Sara Hurvitz's research updates
留下邮箱，当我们发布与 Sara Hurvitz（Fred Hutchinson Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment